Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accelerated Approval Reforms Complicated Because Most Drugs Have Regular Indications Too

Executive Summary

Because Medicare and Medicaid do not reimburse based on indication, it would be hard to target specific accelerated approvals for pricing discounts. This could penalize drug manufacturers even if the accelerated indication represents a minor share of the drug’s use, researchers say.

You may also be interested in...



Accelerated Approvals In Medicaid: Drug Coverage Exclusion Authority Sought In Oregon

If approved, Oregon would be the first state granted the authority to exclude coverage of accelerated approval drugs, even if manufacturers provide the statutory rebates required for Medicaid.

Reforming Accelerated Approval: Three Ideas For Congress

Ideas to reform Accelerated Approval are likely to be debated during the reauthorization of the key US FDA user fee funding authority in 2022. Here are three suggestions for Congress to consider.

Woodcock: High Prices Create Problems For Entire Accelerated Approval Program

Acting FDA commissioner suggests a primary reason for outrage over accelerated approvals is the high costs of certain medications despite their unproven clinical benefits, an issue that is outside of the agency’s purview. Health policy experts says FDA shouldn’t be left off the hook that easily.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS145408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel